Diabetes Research and Clinical Practice - Volume 120 - Supplement 1 - October 2016

118 / 244

of left hand increased to 18.3 ± 1.4 kg (n.s.). Thus, in women,
because the number of subjects was small, the difference was
non-significant statistically.
Conclusion: The results suggest that, in Japanese, obese men
over BMI 25 are likely to have an increased GS than lean men.
But, in the EMPA-REG OUTCOME Study, obese subjects whose
BMI was over 35 were more unlikely to have the benefit of the
heart and vascular complication. This difference will give a
new insight to understand the difference of races.
PD-27
Blood glucose self-monitoring and control for diabetes
patients before and after receiving basic insulin therapies
Pei-Ching LO1*, Yu-Li LEE1. 1Kaohsiung Municipal Ta-Tung
Hospital (Operation under entrustment with Kaohsiung Medical
University Hospital), Taiwan
Purpose: According to the Taiwan Ministry of Health and
Welfare, diabetes is the 5th leading cause of death in 2012.
Meneghini has suggested that early insulin therapy not only
can effectively stabilize blood glucose for relieving liver and
kidney stress, it can further prevent and alleviate comorbid-
ities. Therefore, the diabetes health education team interven-
tion would reinforce patients in monitoring blood glucose,
receiving basic insulin therapy, discussing the changes in
glycated hemoglobin (A1C) and fasting plasma glucose (FPG)
levels before and after insulin therapy for achieving the goal of
optimal diabetes management.
Methods: Outpatients with Type II diabetes who have not
received any insulin therapy, with A1C >8% and FPG > 150 mg/
dL, were selected by the physician and health educator. Patient
consents were collected and a glucose meter was provided for
each patient for the measurement of FPG of at least 3 times a
week. Telephone interviews were performed once a week for
the follow-up analysis of the patient ’s pre- and post-therapy
measurement results.
Results: A total of 31 patients were enrolled in this study, 17 of
which had an A1C of <7% at 3 month follow-up, and 55% of the
31 patients had HA1c levels of <7%. According to the SPSS12
analysis, the A1C levels showed a significant improvement
after therapy (9.58 1.39% to 7.20 1.08%; P = 0.000); the FPG level
was also determined to be significantly improved after therapy
(217.03 48.16 mg/dL to 142.00 27.98 mg/dL; P = 0.000).
Conclusion: After intervention through health education,
with emphasis on the use of blood glucose meter and self-
monitoring, the patients’insulin awareness and acceptance of
treatment were increased, which had furthered improved the
patient self-care and self-management skills. The result is
especially significant in improving glycated hemoglobin
levels. Therefore, we suggest that health education should
emphasize on patient empowerment, and individualized
health education to understand the difficulties for each
patient in the implementing insulin therapy. The improve-
ments in patient practical self-management abilities can be
further applied to other disease management and health
education. Therefore, health education intervention can help
patients overcome treatment difficulties and enable patients
in starting insulin therapy for achieving the goal of efficient of
blood glucose management in patients with Type II diabetes.
PD-28
Comparing the effects between atorvastatin 40 mg and vytorin
10/20 mg on lipoprotein parameters and inflammatory
markers among dyslipidemic T2DM
Chih-Hsun CHU1*, Chun-Chin SUN1, Wan-Chi CHUANG1,
Wei-Cheng CHANG1, Yu-Hsuan TSAI1, Wang-Jung KAO1.
1 Division of Endocrinology and Metabolism, Department of Internal
Medicine, Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan
Background: Our study was aim to evaluate the lipoprotein
parameters and inflammationmodification effects among two
equal cholesterol lowering potency medications, atorvastatin
40 mg and vytorin 10/20 mg (10 mg ezetimibe combined 20 mg
simvastatin).
Materials and methods: The study was a randomized, 12-
week, open labeled study. The study conducted with about 60
dyslipidemic type 2 diabetic patients, who fulfilled additional
criteria of age (20–80 yo), HbA1c≦10%, LDL-C≧130 mg/dL, and
TG < 400 mg/dL. Laboratory evaluations include total choles-
terol, HDL-C, LDL-C, and triglycerides, analyses of ApoA-1, Apo
(a), ox-LDL, IL-6, and hsCRP. All anti-diabetic or anti-hyper-
tensive drugs remained constant 8 weeks before and during
the intervention period. Evaluations are performed before and
immediately after 12-week intervention. Data are reported as
mean ± SEM.
Results: 29 subjects (F/M = 17/12, mean age 60 y/o, DM duration
8.0 years) received atorvastatin 40 mg daily, another 31
subjects (F/M = 18/13, mean age 64 y/o, DM duration 7.8
years) received vytorin (10/20 mg) daily. The results showed
that after three months of treatment, both atorvastatin 40 mg
and vytorin 10/20 mg lowered significant but similar levels of
TC (−93.3 ± 6.4 mg/dL [38%] vs − 94.1 ± 2.9 mg/dL [41%]), LDL-C
(−74.1 ± 4.6 mg/dL [49%] vs − 79.9 ± 2.5 mg/dL [55%]), TG (−39.3
± 13.5 mg/dL [26%] vs −29.8 ± 7.7 mg/dL [20%]), ox-LDL (29.3 ±
3.7 mg/dL [39%] vs 27.0 ± 1.8 mg/dL [36%]). However, no signifi-
cant change of ApoA-1, Apo (a), IL-6 and hsCRP were found
after either atorvastatin or vytorin management.
Conclusion: The effects between Atorvastatin 40 mg and
Vytorin 10/20 mg on lipoprotien parameters were similar.
Both medications significantly lower ox-LDL, however, there
were no effect on Apo (a) and inflammatory markers among
dyslipidemic T2DM.
PD-29
The results of utilizing twice daily premixed insulin and
lifestyle therapy for treating Type II diabetes
Meng-han SHIH1, Shu-Fu LIN1, Szu-Tah CHEN1, Xiao-juan YI1,
Men-gjun HU1, Chiou-Yueh SON 1. 1Linkou Chang Gung Memorial
Hospital, Taiwan
Purpose: This study was aimed to investigate the diabetes
treatment efficiency by utilizing a twice daily premixed insulin
and Steno conversation tool for a series of diabetes education,
diet control, exercise encouragement, glucose monitoring, and
telephone follow-ups.
Methods: This study enrolled Type II diabetes patients in our
hospital that have underwent oral anti-diabetics drug (OAD)
and basic insulin therapy for at least 3 month, yet, with
glycated hemoglobin (A1c) levels of 7.0%, between Feb. 1st and
Aug. 31st, 2015. The patients were switched to a twice daily
premixed insulin therapy, and were also give 4 sessions of diet
and health education classes for the promotion of exercise,
instruction on self-monitoring of blood glucose, and telephone
follow-up management. The patients were regularly assessed
on their number of diabeticmedications, fasting blood glucose,
postprandial blood glucose, A1c, and weight changes, the
patient’s attitudes and compliance towards SMBG, exercise,
and blood glucose management targets.
Results: A total of 51 patients were enrolled in this study
(average age: 64.9 years). During the study period, the patients’
OAD number significantly decreased from 1.8 ± 0.4 to 0.1 ± 0.4
type (0–2 types in reduction; with P < 0.001). The average daily
basal insulin dose at enrollment was 20.9 ± 10.5U. At the end of
the study, the daily premixed insulin dose was 36.8 ± 16.3U
(before breakfast: 20.1 ± 9.4U; before dinner: 16.7 ± 7.6U). The
insulin dosage increase during this period increased by
16.0 ± 12.8U (between 6 and 48U; P < 0.001). The patient SMBG
rate increased from 50% to 95%. The patients with regular
exercise increased from 40% to 85%, and the diabetes A1c
target knowledge increased from 45% to 100%. The FBG and
PBG decreased by 12 ± 42 mg/dL; P = 0.024 (151 ± 28 mg/dL to
138 ± 26 mg/dL) and 70 ± 82 mg/dL; P < 0.001 (244 ± 73 mg/dL to
Poster Presentations / Diabetes Research and Clinical Practice 120S1 (2016) S65–S211 S100